Drug interactions
Betibeglogene autotemcel + Deferasirox
Severity: Major
Betibeglogene autotemcel and Deferasirox: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Some iron chelators can suppress bone marrow function, which may interfere with conditioning, engraftment of gene-modified cells, and infection risk. Deferasirox can cause cytopenias, so overlap with transplant conditioning and early recovery is undesirable.
What this interaction means in plain words
Betibeglogene autotemcel and Deferasirox can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Potential additive myelosuppression that may impair hematopoietic recovery after gene therapy.
What to do
Stop deferasirox at least 7 days before conditioning and avoid it for about 6 months after infusion. Use phlebotomy or a non-myelosuppressive chelator if iron removal is needed.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Betibeglogene autotemcel and Deferasirox, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Deferasirox
Frequently asked questions
Can I take Betibeglogene autotemcel with Deferasirox?
MediHelp rates the interaction as major. Betibeglogene autotemcel and Deferasirox can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Some iron chelators can suppress bone marrow function, which may interfere with conditioning, engraftment of gene-modified cells, and infection risk. Deferasirox can cause cytopenias, so overlap with transplant conditioning and early recovery is undesirable.
How serious is the interaction between Betibeglogene autotemcel and Deferasirox?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Stop deferasirox at least 7 days before conditioning and avoid it for about 6 months after infusion. Use phlebotomy or a non-myelosuppressive chelator if iron removal is needed.
What other medicines interact with Deferasirox?
MediHelp also lists interactions of Deferasirox with, for example, Acetylsalicylic acid, Alosetron, Aluminum hydroxide. The full list is on the Deferasirox page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
